Additionally, tumor-infiltrating NK cells (CD45+) were enriched from < 5% in the saline group to 35% and 75% in the cmLumiOpto and cmLumiOpto/PARPi treatment groups, respectively. The gene discussed is PTPRC; the disease is neoplasm.